Skip to Main Navigation

Niger COVID-19 Emergency Response Project - Additional Financing

Abstract*

The Additional Financing will support expanding activities of Niger COVID-19 Emergency Response Project, under the COVID-19 Strategic Preparedness and Response Program using the Multiphase Programmatic Approach. The primary objectives of the AF are to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in Niger through vaccination system strengthening, and to further strengthen preparedness and...

* The project abstract is drawn from the PAD, SAR or PGD and may not accurately reflect the project's current nature

Show More

Development Objective

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Niger

Key Details

Project Details

  • P176345

  • Active

  • Cedric Ndizeye

  • Republic of Niger

  • Niger

  • May 26, 2021

  • (as of board presentation)

    June 25, 2021

  • N/A

  • US$ 29.20 million

  • N/A

  • N/A

  • December 31, 2024

  • Yes

  • BANK APPROVED

  • P173846

  • November 8, 2022

  • Notes

Finances

Financing Plan (US$ Millions)

No data available.
Financier Commitments
IDA Credit 14.00
IDA Grant 14.00
Energy Sector Management Assistance Program 1.20

Total Project Financing (US$ Millions)

Product Line IBRD/IDA
IBRD Commitment N/A
IDA Commitment 28.00
IBRD + IDA Commitment 28.00
Lending Instrument
Grant Amount 1.20
Total Project Cost** 29.20

Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025

Download:
No data available.
Financier Approval Date Closing Date Principal Disbursed Repayments Interest, Charges & Fees

Detailed Financial Activity as of March 31, 2025

Download:
No data available.
Period Financier Transaction Type Amount (US$)

Footnotes

Ratings

IMPLEMENTATION RATINGS

No data available.

COMPLETION RATINGS

No data available.

INDEPENDENT EVALUATION RATINGS

No data available.

Results Framework

No data available.